HER2-positive Breast Cancer Clinical Trials

77 recruiting

HER2-positive Breast Cancer Trials at a Glance

82 actively recruiting trials for her2-positive breast cancer are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 34 trials, with the heaviest enrollment activity in Boston, Beijing, and New York. Lead sponsors running her2-positive breast cancer studies include Shu Wang, Dana-Farber Cancer Institute, and H. Lee Moffitt Cancer Center and Research Institute.

Browse her2-positive breast cancer trials by phase

Treatments under study

About HER2-positive Breast Cancer Clinical Trials

Looking for clinical trials for HER2-positive Breast Cancer? There are currently 77 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-positive Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-positive Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 82 trials

Recruiting
Phase 2

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled26 locationsNCT07102381
Recruiting
Phase 1

HER2 Vaccine for Locally Advanced Breast Cancer

Breast CancerHER2-positive Breast Cancer
Pravin T.P Kaumaya36 enrolled1 locationNCT06949410
Recruiting
Phase 2

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute500 enrolled53 locationsNCT04893109
Recruiting

Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients

HER2-positive Breast Cancer
Giampaolo Bianchini10 enrolled1 locationNCT06518382
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 3

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460
Recruiting
Phase 2

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

HER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting
Phase 1

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute28 enrolled1 locationNCT05378464
Recruiting
Phase 3

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

HER2-positive Breast CancerBreast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Not Applicable

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast CancerHER2-positive Breast Cancer
Brigham and Women's Hospital214 enrolled1 locationNCT04030507
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Breast CancerHER2-positive Breast CancerBreast Cancer Stage IV
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07459673
Recruiting
Phase 2

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute53 enrolled1 locationNCT05325632
Recruiting
Phase 2

A Study of Surgery and Radiotherapy in People With Breast Cancer

Metastatic Breast CancerHER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center162 enrolled7 locationsNCT07053085
Recruiting
Phase 3

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.540 enrolled1 locationNCT07377643
Recruiting
Not Applicable

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

HER2-positive Breast Cancer
Fundacio Clinic Barcelona304 enrolled29 locationsNCT06446882
Recruiting
Phase 2

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

HER2-positive Breast CancerLMD
Sunnybrook Health Sciences Centre30 enrolled2 locationsNCT06016387
Recruiting
Phase 2

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast CancerHER2-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
University of Chicago74 enrolled4 locationsNCT06348134